Phacilitate

  • About Us
    • Advisory Board
  • Insights and Resources
        • All Insights and Resources
          The latest and greatest Insights Phacilitate has to offer, across all our key sectors and mediums

        • Webinar Library
          View upcoming and past webinars about world of advanced therapies

           

          The Phacilitate Podcast
          Insightful conversations with industry leaders

        • Content Services
          We create game-changing content that empowers the advanced therapies industry

          • Industry Insights
            • Clinical Trials
            • Collaborations, Mergers and Acquisitions
            • Finance and Investment
            • GMP
            • Patient Access and Engagement
            • Regulatory and Standards
            • Reimbursement
            • Strategy
          • Manufacturing
            • Automation and Digitisation
            • Characterisation
            • CMC
            • GMP
            • Logistics
            • Partnering
            • Point of Care
            • Raw Materials
            • Scaling Up
            • Skills, Talent and Development
            • Supply Chain
          • Techniques
            • Allogeneic
            • Autologous
            • CAR-X
            • Cell Therapy
            • Gene Editing
            • Gene Therapy
            • NKx
            • Stem Cells
            • Viral/Non-viral Vectors
  • Latest News
  • Events
  • The Directory
    • The Cell and Gene Directory
    • Manufacturing Capacity Map
  • Membership
    • Phacilitate Network
    • Women in Advanced Therapies
Back
  • About Us
    • Advisory Board
  • Insights and Resources
        • All Insights and Resources
          The latest and greatest Insights Phacilitate has to offer, across all our key sectors and mediums

        • Webinar Library
          View upcoming and past webinars about world of advanced therapies

           

          The Phacilitate Podcast
          Insightful conversations with industry leaders

        • Content Services
          We create game-changing content that empowers the advanced therapies industry

          • Industry Insights
            • Clinical Trials
            • Collaborations, Mergers and Acquisitions
            • Finance and Investment
            • GMP
            • Patient Access and Engagement
            • Regulatory and Standards
            • Reimbursement
            • Strategy
          • Manufacturing
            • Automation and Digitisation
            • Characterisation
            • CMC
            • GMP
            • Logistics
            • Partnering
            • Point of Care
            • Raw Materials
            • Scaling Up
            • Skills, Talent and Development
            • Supply Chain
          • Techniques
            • Allogeneic
            • Autologous
            • CAR-X
            • Cell Therapy
            • Gene Editing
            • Gene Therapy
            • NKx
            • Stem Cells
            • Viral/Non-viral Vectors
  • Latest News
  • Events
  • The Directory
    • The Cell and Gene Directory
    • Manufacturing Capacity Map
  • Membership
    • Phacilitate Network
    • Women in Advanced Therapies
Join Today
Sign In
Sign In
Join Today

Cell Therapy to Restore Function in Heart Failure Dosed to First Patient, Novo Nordisk and Heartseed Announce

Banner
Anna Osborne
15 February 2023
SHARE NOW
Cell Therapy
Clinical Trials
Collaborations, Mergers & Acquisitions
Regulatory & Standards
Stem Cells
Heartseed Inc (Tokyo, Japan) and Novo Nordisk (Bagsværd, Denmark) have announced that the first patient has been dosed with HS-001 in Heartseed’s Phase I/II clinical study on advanced heart failure.

Heart failure is a chronic and progressive condition limiting heart function and effecting more than 65 million people worldwide.

There are currently no cures for heart failure. More than half of the people diagnosed with heart failure will die within five years.

Under the two Companies’ 2021 Partnership agreement, Heartseed maintain the rights to develop HS-001 in Japan, with the therapy being co-commercialized by both Heartseed and Novo Nordisk in this location.

Elsewhere Novo Nordisk will solely develop, manufacture and commercialize the therapy, with Heartseed set to receive milestone payments and royalties of annual net sales outside of Japan.

“Cell therapy holds the promise to offer truly disease-modifying treatments for people living with serious chronic disease. We are very pleased that our partners from Heartseed have begun clinical testing of this innovative approach to treating heart failure,” said Jacob Sten Petersen, corporate vice president of Cell Therapy R&D in Novo Nordisk.

How are you enjoying this news article? Let us know your thoughts, here >>

 

HS-001 is an investigational cell therapy for advanced heart failure caused by ischemic heart diseases, under Phase I/II evaluation in the 52-week, open-label, dose-escalation study, Lapis.

The cell therapy is designed to restore heart muscle function and consists of clusters of purified heart muscle cells induced from iPSCs.

Previous preclinical studies indicate that iPSC-derived cardiomyocytes have the ability to improve heart function.

HS-001 is transplanted into the patients diseased heart tissue during a coronary artery bypass graft procedure.

Lapis will see a total of 10 patients enrolled in 2 dose cohorts – 50 million, and 150 million cardiomyocytes.

The primary endpoint of the study will be determined by safety at 26-weeks post-transplantation, with secondary efficacy endpoints to include left ventricular ejection fraction and myocardial wall motion.

Initial 4-week data gathered from the first patient dosed in the Lapis study has been evaluated by an independent safety committee and approved for continuation.

“As a cardiologist, I have been working for many years to realize cardiac regeneration medicine in order to treat patients with heart failure whose heart function has deteriorated to the point where they are unable to live their daily lives. To achieve this goal, we established Heartseed and have continued our development with patient safety and benefit as our top priority,” said Keiichi Fukuda, CEO of Heartseed.

Source: Novo Nordisk Press Release and Heartseed Inc Press Release 

 


While we have you…

We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.

More like this

Taysha Gene Therapies Halts its TSHA-120 Program for Giant Axonal Neuropathy Treatment

Taysha is discontinuing the development of TSHA-120 in GAN following the Type C meeting feedback from the FDA
21 September 2023

Oxford Biomedica Explores Acquisition of ABL Europe in Collaboration with Institut Mérieux

Oxford Biomedica in Exclusive Talks to Acquire ABL Europe from Institut Mérieux.
20 September 2023

The Cell & Gene Therapy Manufacturing Capacity Map

The only live, interactive manufacturing capacity compendium for the advanced therapies industry.
20 September 2023

Discover more like this

Taysha Gene Therapies Halts its TSHA-120 Program for Giant Axonal Neuropathy Treatment

Oxford Biomedica Explores Acquisition of ABL Europe in Collaboration with Institut Mérieux

The Cell & Gene Therapy Manufacturing Capacity Map

Broken String Bioscience Closes $15M Series A Funding Round

FDA Delays the Review of Iovance’s BLA Treatment of Advanced Melanoma

logo_footer
logo_mobile_footer
Company
  • About Us
  • Events
  • Contact Us
Resources
  • Insights and Resources
  • Latest News
  • Phacilitate Podcast
  • Content Services
Network
  • Sign In
  • Join Today
social_icon Linkedin
social_icon Twitter

Clarion Events Limited is registered in England and Wales, Company Number 00454826, VAT No. GB 843845601 Registered Office: Bedford House, 69-79 Fulham High Street, London, SW6 3JW, United Kingdom.

  • Privacy Policy
  • Code of Conduct
  • Terms & Conditions
  • Cookies
Phacilitate is a part of Clarion Events Limited. © Phacilitate 2022